<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zajac P</submitter><funding>Swiss National Science Foundation</funding><pagination>18</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5340762</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4</volume><pubmed_abstract>MAGE-A antigens are expressed in a variety of cancers of diverse histological origin and germinal cells. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies. Here, we (i) review past and ongoing clinical studies targeting these antigens, (ii) analyze advantages and disadvantages of different therapeutic approaches, and (iii) discuss possible improvements in MAGE-A-specific immunotherapies.</pubmed_abstract><journal>Frontiers in medicine</journal><pubmed_title>MAGE-A Antigens and Cancer Immunotherapy.</pubmed_title><pmcid>PMC5340762</pmcid><funding_grant_id>149745</funding_grant_id><funding_grant_id>310030_149745</funding_grant_id><funding_grant_id>310030</funding_grant_id><pubmed_authors>Tornillo L</pubmed_authors><pubmed_authors>Spagnoli GC</pubmed_authors><pubmed_authors>Iezzi G</pubmed_authors><pubmed_authors>Mengus C</pubmed_authors><pubmed_authors>Sadowski C</pubmed_authors><pubmed_authors>Trella E</pubmed_authors><pubmed_authors>Zajac P</pubmed_authors><pubmed_authors>Schultz-Thater E</pubmed_authors></additional><is_claimable>false</is_claimable><name>MAGE-A Antigens and Cancer Immunotherapy.</name><description>MAGE-A antigens are expressed in a variety of cancers of diverse histological origin and germinal cells. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies. Here, we (i) review past and ongoing clinical studies targeting these antigens, (ii) analyze advantages and disadvantages of different therapeutic approaches, and (iii) discuss possible improvements in MAGE-A-specific immunotherapies.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2024-02-14T22:06:27.754Z</modification><creation>2019-03-27T02:38:02Z</creation></dates><accession>S-EPMC5340762</accession><cross_references><pubmed>28337438</pubmed><doi>10.3389/fmed.2017.00018</doi></cross_references></HashMap>